EA200700173A1 - Пористые таблетки в качестве носителей для жидких композиций - Google Patents

Пористые таблетки в качестве носителей для жидких композиций

Info

Publication number
EA200700173A1
EA200700173A1 EA200700173A EA200700173A EA200700173A1 EA 200700173 A1 EA200700173 A1 EA 200700173A1 EA 200700173 A EA200700173 A EA 200700173A EA 200700173 A EA200700173 A EA 200700173A EA 200700173 A1 EA200700173 A1 EA 200700173A1
Authority
EA
Eurasian Patent Office
Prior art keywords
loaded
liquid compositions
media
batch
pharmaceutically acceptable
Prior art date
Application number
EA200700173A
Other languages
English (en)
Other versions
EA013632B1 (ru
Inventor
Пер Хольм
Янни Эгесков Хольм
Томас Руланд
Симон Дальсгор Нильсен
Original Assignee
Лайфсайкл Фарма А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лайфсайкл Фарма А/С filed Critical Лайфсайкл Фарма А/С
Publication of EA200700173A1 publication Critical patent/EA200700173A1/ru
Publication of EA013632B1 publication Critical patent/EA013632B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Новый таблетированный продукт, который легким, адаптируемым и воспроизводимым способом можно загрузить относительно большим количеством фармацевтически приемлемой жидкой композиции, например, несущей терапевтически, профилактически и/или диагностически активное вещество. Новый загружаемый таблетированный продукт можно получить партиями большого масштаба и хранить до применения, и каждую партию или подпартию можно загрузить одним и тем же или разными фармацевтически приемлемыми жидкими композициями и/или активными веществами. Загружаемая таблетка согласно изобретению имеет пористость 30 об./об.% или больше. Изобретение предлагает также таблетки, которые были загружены такой жидкой композицией, а также способ их получения.
EA200700173A 2004-06-28 2005-06-27 Пористые таблетки в качестве носителей для жидких композиций EA013632B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200401011 2004-06-28
PCT/DK2005/000436 WO2006000229A2 (en) 2004-06-28 2005-06-27 Porous tablets as carriers for liquid formulations

Publications (2)

Publication Number Publication Date
EA200700173A1 true EA200700173A1 (ru) 2007-04-27
EA013632B1 EA013632B1 (ru) 2010-06-30

Family

ID=34973932

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200700173A EA013632B1 (ru) 2004-06-28 2005-06-27 Пористые таблетки в качестве носителей для жидких композиций

Country Status (11)

Country Link
US (2) US20090181083A1 (ru)
EP (1) EP1765297A2 (ru)
JP (1) JP5403912B2 (ru)
KR (1) KR101352299B1 (ru)
CN (2) CN1976751A (ru)
AU (1) AU2005256322C1 (ru)
BR (1) BRPI0512660A (ru)
CA (1) CA2572180C (ru)
EA (1) EA013632B1 (ru)
MX (1) MXPA06014894A (ru)
WO (1) WO2006000229A2 (ru)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
AU2007203715B2 (en) * 2006-01-05 2012-08-02 Veloxis Pharmaceuticals A/S Disintegrating loadable tablets
SI22237A (sl) * 2006-04-06 2007-10-31 Igc Center D.O.O. Porozne tablete za naknadno polnjenje z zdravilnouäśinkovino
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
DE102006054638B4 (de) * 2006-11-16 2014-12-04 Laburnum Gmbh Pharmazeutische Einzeldosisform
LT2487162T (lt) 2007-02-23 2016-11-10 Gilead Sciences, Inc. Terapinių agentų farmakokinetinių savybių moduliatoriai
KR100883825B1 (ko) * 2007-04-18 2009-02-16 김남호 규소 조성물 및 이를 함유한 음용수 제조방법
GB0709541D0 (en) * 2007-05-17 2007-06-27 Jagotec Ag Pharmaceutical excipient
US10039718B2 (en) 2008-05-02 2018-08-07 Gilead Sciences, Inc. Use of solid carrier particles to improve the processability of a pharmaceutical agent
BRPI1009121A2 (pt) 2009-03-04 2018-06-19 Orexo Ab formulações resistentes a abuso
CN102421419B (zh) 2009-05-08 2016-05-04 奥瑞克索股份公司 用于持续药物传递的包含地聚合物粘合剂的组合物
CN101991513B (zh) * 2009-08-12 2013-06-12 陈励 用于个人护理的化妆品和药品的生产原料
US9370493B2 (en) 2009-10-23 2016-06-21 Pronova Biopharma Norge As Coated capsules and tablets of a fatty acid oil mixture
CN102038638B (zh) * 2009-10-26 2012-12-26 海口市制药厂有限公司 盐酸克林霉素注射液及其制备方法
WO2011154009A1 (en) 2010-06-10 2011-12-15 Lifecycle Pharma A/S Composition comprising an active principle in an amorphous form and a porous adsorbent material
WO2011154013A1 (en) 2010-06-10 2011-12-15 Lifecycle Pharma A/S Pharmaceutical composition comprising fenofibric acid
WO2011154012A1 (en) 2010-06-10 2011-12-15 Lifecycle Pharma A/S Mini-tablets comprising porous adsorbent material
CN101919822B (zh) * 2010-07-16 2013-10-23 钟术光 综合性能改善的片剂及其制备方法
WO2012032337A2 (en) 2010-09-07 2012-03-15 Orexo Ab A transdermal drug administration device
CN102018960A (zh) * 2010-12-01 2011-04-20 安徽省皖北药业股份有限公司 一种保持克林霉素磷酸酯注射液质量稳定性的方法
CN102382125B (zh) * 2011-07-29 2014-04-09 成都市考恩斯科技有限责任公司 头孢妥仑的水溶性复合物及其制备方法和相应药物制剂
ES2924478T3 (es) 2012-03-15 2022-10-07 Boehringer Ingelheim Vetmedica Gmbh Formulación de comprimidos farmacéuticos para el sector médico veterinario, método de producción y uso de los mismos
EP2833740B1 (en) 2012-04-04 2016-09-14 Pronova BioPharma Norge AS Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof
WO2013150384A1 (en) 2012-04-04 2013-10-10 Pronova Biopharma Norge As Compositions comprising omega-3 fatty acids and vitamin d for psoriasis, and methods and uses thereof
CN105377235A (zh) 2013-07-19 2016-03-02 勃林格殷格翰动物保健有限公司 含有防腐的醚化的环糊精衍生物的液体水性药物组合物
BR112016011111B1 (pt) 2013-12-04 2022-11-16 Boehringer Ingelheim Vetmedica Gmbh Composições farmacêuticas aprimoradas de pimobendan
KR101556568B1 (ko) * 2013-12-17 2015-10-01 주식회사 대웅제약 콜린 알포세레이트를 함유하는 필름코팅정 및 이의 제조방법
PL3157508T3 (pl) * 2014-06-19 2021-05-17 Solural Pharma ApS Związki lipofilowe w postaci stałej dawkowane doustnie
CN104523592B (zh) * 2015-01-26 2017-03-15 湖北工业大学 甲泼尼龙醋酸酯注射用自微乳制剂及其制备方法
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
MX2019002835A (es) 2016-09-13 2019-09-04 Allergan Inc Composiciones no proteínicas de toxina clostridial.
JP2019007235A (ja) * 2017-06-26 2019-01-17 アイシン精機株式会社 洗浄便座装置
MX2020007435A (es) 2018-02-01 2020-09-14 Dow Global Technologies Llc Mezcla madre con resina portadora de poliolefina semicristalina.
CA3086048A1 (en) 2018-02-01 2019-08-08 Dow Global Technologies Llc Masterbatch with semi-crystalline polyolefin carrier resin
CN108517365B (zh) * 2018-03-27 2021-03-19 东北农业大学 一种提高猪天然免疫力的Sp100分子标记育种方法及其应用
JP2021528452A (ja) * 2018-06-25 2021-10-21 タイタン ファーマシューティカルズ インコーポレイテッド インプラントとして使用するための装填可能な多孔質構造
CN111067876B (zh) * 2019-12-04 2022-08-16 宁夏大学 一种α-亚麻酸双层片及其制备方法
CN110974919A (zh) * 2019-12-23 2020-04-10 湛江寸草制药有限公司 一种神阙穴肚脐给药的药物载体脐炭丸及其制备方法与应用
CN111905836B (zh) * 2020-08-14 2024-08-13 上海组波智能仪器科技有限公司 一种多孔塑料化学试剂载体及其制备方法和应用
KR102366486B1 (ko) * 2021-06-15 2022-02-23 대한민국 천공성해충 피해방지제 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5444034A (en) * 1977-09-14 1979-04-07 Kanebo Ltd Easily absorbable nifedipine composition and anti- stenocardia containing said composition
EP0001247A1 (en) * 1977-09-14 1979-04-04 Kanebo, Ltd. Pharmaceutical preparation containing nifedipine and a method for producing the same.
TW222585B (ru) * 1992-09-11 1994-04-21 Hoechst Ag
JP2700141B2 (ja) * 1993-09-17 1998-01-19 富士化学工業株式会社 リン酸水素カルシウム及びその製法並びにそれを用いた賦形剤
KR100618234B1 (ko) * 1998-12-23 2006-09-01 알자 코포레이션 다공성 입자를 포함하는 제형
US6399591B1 (en) * 2000-01-19 2002-06-04 Yung-Shin Pharmaceutical Ind. Co., Ltd. Chargeable pharmaceutical tablets
US20050147666A1 (en) * 2002-03-06 2005-07-07 Kyowa Hakko Kogyo Co., Ltd. Tablets quickly disintegrating in oral cavity
CA2570802A1 (en) * 2004-06-28 2006-01-05 H. Lundbeck A/S Porous article for delivering chemical substances
AU2007203715B2 (en) * 2006-01-05 2012-08-02 Veloxis Pharmaceuticals A/S Disintegrating loadable tablets
WO2011120530A1 (en) * 2010-03-31 2011-10-06 Lifecycle Phama A/S Porous tablets as carriers for liquid formulations

Also Published As

Publication number Publication date
BRPI0512660A (pt) 2008-04-01
EA013632B1 (ru) 2010-06-30
WO2006000229A3 (en) 2006-08-24
CA2572180A1 (en) 2006-01-05
US20150164812A1 (en) 2015-06-18
CN101001613B (zh) 2010-09-29
JP2008504308A (ja) 2008-02-14
KR101352299B1 (ko) 2014-02-17
CA2572180C (en) 2014-05-20
AU2005256322C1 (en) 2011-07-07
CN1976751A (zh) 2007-06-06
WO2006000229A2 (en) 2006-01-05
AU2005256322B2 (en) 2011-03-03
EP1765297A2 (en) 2007-03-28
AU2005256322A1 (en) 2006-01-05
MXPA06014894A (es) 2007-03-21
KR20070035033A (ko) 2007-03-29
JP5403912B2 (ja) 2014-01-29
CN101001613A (zh) 2007-07-18
US20090181083A1 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
EA200700173A1 (ru) Пористые таблетки в качестве носителей для жидких композиций
RU2008136408A (ru) Фармацевтическая композиция
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
RU2008126743A (ru) Способ получения фармацевтической композиции
MY144897A (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
ATE424848T1 (de) Pharmazeutische zusammensetzungen für die kontrollierte freigabe von biologischen wirkstoffen
DK1973529T3 (da) Fyldbar tablet, som er i stand til at falde hen
Fetherston et al. Partial protection against multiple RT-SHIV162P3 vaginal challenge of rhesus macaques by a silicone elastomer vaginal ring releasing the NNRTI MC1220
WO2004026836A8 (en) 1-pyridin-4-yl-urea derivatives
MA29169B1 (fr) Formulations intraveineuses d'inhibiteurs de la pde-5
NO20060955L (no) Farmasoytisk sammensetning som er nyttig til stamcellemobilisering
DE69527711D1 (de) Verfahren und apparat zur herstellung von schnelllöslichen dosierungseinheiten und daraus erhältliches produkt
Huang et al. Induction of cyclooxygenase-2 mRNA and protein expression by epoxy resin and zinc oxide-eugenol based root canal sealers in human osteoblastic cells
MXPA05011497A (es) Derivados de tropano y su uso como inhibidores de la enzima de conversion de angiotensina (ace).
WO2006021401A3 (en) Bicylononene derivatives
Veronica et al. Insights into the moisture scavenging properties of different types of starch in tablets containing a moisture-sensitive drug
Huang et al. Prevention of the epoxy resin-based root canal sealers-induced cyclooxygenase-2 expression and cytotoxicity of human osteoblastic cells by various antioxidants
AR111182A1 (es) Composición farmacéutica de análogos de deutetrabenazina, su preparación y uso
TW200621774A (en) Bicyclononene derivatives
MXPA05010254A (es) Composicion farmaceutica que contiene complejo de platino como sustancia activa y metodo de fabricacion de la misma.
Velmurugan et al. Formulation and in vitro evaluation of glipizide mucoadhesive buccal tablets
ES2529568T3 (es) Uso de cuerpos moldeados para aplicación externa
GB1464467A (en) Pharmaceutical composition for the treatment of coronary
DE602004022515D1 (de) Fenofibrate tablett und verfahren zur herstellung
TR201915787A2 (tr) Bosentan monohi̇drat yüklenmi̇ş sivi kendi̇li̇ği̇nden nanoemülsi̇fi̇ye i̇laç taşiyici si̇stem ve tablet formülasyonu

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM